Progyny, Inc.

Health Care
Misc Health and Biotechnology Services
www.progyny.com

Earnings Score
Moat Score

Market Cap $1.99B
PE 37
Debt -
Cash $162.31M
EV -
FCF $173.70M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$54.34M
EBIT	$83.20M
ROE	13%
ROA	14%
FCF	$173.70M
Equity	$422.06M
Growth Stability	88%
PE	36.68
PEG	1.86
PB	4.72
P/FCF	11.47
P/S	1.71
Price/Cash	0.08
Net Margins	5%
Gross Margins	22%
Op. Margins	7%
Earnings CAGR	12%
Sales Growth YoY	11%
Sales Growth QoQ	4%
Sales CAGR	48%
FCF CAGR	95%
Equity CAGR	35%
Earnings Stability	-0.29
Earnings Growth YoY	-22%

Earnings Growth QoQ	1%
Earnings CAGR 5Y	20%
Sales CAGR 5Y	41%
FCF CAGR 5Y	95%
Equity CAGR 5Y	39%
Earnings CAGR 3Y	32%
Sales CAGR 3Y	32%
FCF CAGR 3Y	132%
Equity CAGR 3Y	19%
Market Cap	$1.99B
Revenue	$1.17B
Assets	$607.10M
Cash	$162.31M
Shares Outstanding	85.31M
Earnings Score	6%
Moat Score	89%
Working Capital	304.09M
Current Ratio	2.8
Gross Profit	$253.36M
Shares Growth 3y	-1%
Equity Growth QoQ	-3%
Equity Growth YoY	-24%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics.

SEC Filings

Direct access to Progyny, Inc. (PGNY) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Progyny, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Progyny, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 12%

Stability -29%

loading chart...

Progyny, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Progyny, Inc..

Years

Calculation mode

= $667B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$174M	$339M	$663M	$1.3B	$2.5B	$4.9B	$9.7B	$19B	$37B	$72B	$141B	$1.4T
DCF		$309M	$548M	$974M	$1.7B	$3.1B	$5.5B	$9.7B	$17B	$31B	$54B	$544B
Value	$667B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-28%	-5%	-4%	13%	13%	4%	6%	5%	5%
ROA	-	-8%	6%	3%	9%	5%	9%	14%	14%
ROE	-	6%	-7%	28%	26%	8%	11%	13%	13%

Bad Net Margins (4.66%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	0.15	-	-	-	-	-	-	-
Debt over Equity	-	-0	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	100%	88%	100%	100%	88%

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Neutral Graham’s Stability (88%)

The company has a stability in its earnings that is not too good nor too bad.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	117%	118%	50%	45%	57%	38%	7%	41%
Earnings YoY growth	-	-59%	55%	-642%	42%	-54%	104%	-12%	20%
Equity YoY growth	-	-3%	-220%	46%	51%	50%	47%	-24%	39%
FCF YoY growth	-	-117%	-365%	-883%	-32%	223%	140%	-6%	95%